Angina Pectoris Drugs Market Report 2024-2033: Size, Share, Growth, Trends, Analysis, Outlook, Competitive Landscape

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Angina Pectoris Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $15.48 billion In 2028 At A CAGR Of 5.6% :
The angina pectoris drugs market size has grown strongly in recent years. It will grow from $11.82 billion in 2023 to $12.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high prevalence of cardiovascular diseases, aging population demographics, lifestyle factors, increase in hypertension rates, diabetes prevalence ..

The angina pectoris drugs market size is expected to see strong growth in the next few years. It will grow to $15.48 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising global obesity rates, advancements in precision medicine, focus on preventive cardiology, patient education initiatives, research on novel therapeutic targets .. Major trends in the forecast period include telemedicine for remote monitoring, real-world evidence and outcome studies, patient-centric medication education, strategic alliances for market access, regulatory advances and expedited approvals..

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

Angina Pectoris Drugs Market Major Segments
The angina pectoris drugs market covered in this report is segmented -
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal's Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Key Driver - Surging Prevalence Of Chronic Angina Pectoris Propels Growth In The Angina Pectoris Drug Market
The increasing prevalence of chronic angina pectoris is expected to propel the growth of the angina pectoris drug market going forward. Chronic angina pectoris is chest pain or discomfort caused by reduced blood flow to the heart muscle. Angina pectoris drugs are vital in treating chronic angina. They can provide several benefits to those suffering from this illness, including coronary heart disease, cardiovascular disease, high blood pressure, and being overweight or obese. For instance, in May 2023, according to the Centers for Disease Control and Prevention Highlights, a US-based intergovernmental organization, coronary heart disease killed round 375,476 people in 2021 where, roughly one in every twenty people aged 20 and over (5%). Further, in 2021, almost 2 out of every 10 deaths from coronary artery disease are expected to occur in people under 65. Furthermore, in December 2022, according to the National Library of Medicine, a national center for biological information, Angina affects more than 10 million people in the United States, with more than 500,000 new diagnoses each year. Therefore, the increasing prevalence of chronic angina pectoris is driving the growth of the angina pectoris drug market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=10797&type=smp

Prominent Trend - Hikma Pharmaceuticals Unveils Labetalol Hydrochloride Injection, Usp, Marking A Milestone In Angina Pectoris Drug Market

Product innovation is a key trend gaining popularity in angina pectoris drugs market. Major companies operating in the angina pectoris drug market are adopting new technologies to sustain their position in the market. For instance, in March 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Labetalol Hydrochloride Injection, USP, in a prefilled syringe. The Food and Drug Administration of the United States has authorized this product. In hospitals, 10 mg/2 mL PFS is used to treat severe hypertension and lower blood pressure.

Angina Pectoris Drugs Market Players
Major companies operating in the angina pectoris drugs market report are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Amgen Inc., Gilead Sciences Inc., Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AbbVie Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Sanofi SA, Sun BioPharma Inc., Atox Bio Inc., CalciMedica Inc., D-Pharm Ltd., Dynavax Technologies Corporation, Fresenius SE & Co KGaA, Olympus Corporation, SCM Lifescience Co. Ltd., Allergan plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Johnson & Johnson,

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the angina pectoris drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Angina Pectoris Drugs Market Report Structure
3. Angina Pectoris Drugs Market Trends And Strategies
4. Angina Pectoris Drugs Market - Macro Economic Scenario
5. Angina Pectoris Drugs Market Size And Growth
…..
27. Angina Pectoris Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.